Pembrolizumab for children with advanced, hard-to-treat cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Skin clinical trials.
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 6 months to under 18 years when you sign consent
- Have advanced cancer (solid tumor or lymphoma) that cannot be cured, and prior treatment has failed or isn’t available
- Have available tumor tissue (from a past biopsy or a new biopsy if needed)
- Have measurable tumors that can be tracked on scans (or meet the lymphoma measurement rules)
- Be well enough for treatment (good “organ function”) and scores showing you can do daily activities (Lansky/Karnofsky at least 50)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This trial studies pembrolizumab (an immune therapy) in children and young people with hepatocellular carcinoma (HCC) that has returned or did not respond to earlier treatment. The goal is to see whether it can shrink tumors and help control the cancer.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial studies pembrolizumab, an immunotherapy medicine, in people with thymoma or thymic cancer that cannot be removed with surgery. It aims to see how well the treatment works and how safe it is, including whether your immune system can help control the cancer.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.